Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Abstract

Emerging evidence has suggested a link between new-onset psoriasis and both COVID-19 infection and vaccination, though findings have been limited by small case numbers and lack of adequate control groups. This retrospective cohort study used electronic health records from the US Collaborative Network of TriNetX from January 2020 to January 2025 to compare the risk of developing new-onset psoriasis in individuals with confirmed COVID-19 infection and no vaccination history vs those vaccinated without prior infection. Propensity score matching was applied to balance demographics, comorbidities, and psoriasis risk factors. The primary outcome was a new diagnosis of psoriasis (ICD10-CM: L40.0–5) within 3 months following infection or vaccination. Subgroup analyses assessed the specific codes L40.0-5 separately. Kaplan–Meier survival analysis and Cox proportional hazards models were used to compare outcomes. Patients with COVID-19 infection had a significantly higher risk of developing psoriasis compared with vaccinated individuals (HR 1.30; 95% CI, 1.14–1.49; p < 0.001). Increased risks were also observed for psoriatic arthritis and pustulosis palmaris et plantaris. These findings suggest a potential triggering role of infection in psoriasis pathogenesis and support the safety profile of vaccination. Further studies are needed to confirm causality and guide clinical decision-making.

OriginalspracheEnglisch
Aufsatznummeradv44217
ZeitschriftActa Dermato-Venereologica
Jahrgang106
Seiten (von - bis)adv44217
ISSN0001-5555
DOIs
PublikationsstatusVeröffentlicht - 2026

Fördermittel

This work was supported by the Cluster of Excellence “Precision Medicine in Chronic Inflammation” (EXC 2167), Individual Research Grant LU 877/25-1 and the Clinician Scientist School Lübeck of the Deutsche Forschungsgemeinschaft and the Schleswig-Holstein Excellence-Chair Program from the State of Schleswig-Holstein. PC was supported by Region Stockholm, the Tore Nilson Foundation, and Karolinska Institutet. Data availability statement: The data underlying this article were provided by TriNetX under licence and with permission. Data sharing upon request to TriNetX via the corresponding author. Ethics declaration and trial registry information: The use of the TriNetX platform for research was approved by the Swedish Ethical Review Authority (diary number 2025-03805-02).

TrägerTrägernummer
Tore Nilsons Stiftelse för Medicinsk Forskning

    UN SDGs

    Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

    1. SDG 3 – Gesundheit und Wohlergehen
      SDG 3 – Gesundheit und Wohlergehen

    Strategische Forschungsbereiche und Zentren

    • Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)
    • Zentren: Center for Research on Inflammation of the Skin (CRIS)

    DFG-Fachsystematik

    • 2.21-05 Immunologie
    • 2.22-19 Dermatologie

    Coronavirus-Bezug

    • Forschung zu SARS-CoV-2 / COVID-19

    Fingerprint

    Untersuchen Sie die Forschungsthemen von „COVID-19 Infection vs Vaccination and the Risk of New-onset Psoriasis“. Zusammen bilden sie einen einzigartigen Fingerprint.

    Zitieren